Table 1 Baseline characteristics and outcomes

Age (years)

64 (10)

79 (7)

< 0.001

Male sex, n (%)

122 (87)

78 (77)

0.04

Ischemic cardiomyopathy, n (%)

71 (50)

63 (62)

0.08

Atrial fibrillation, n (%)

66 (47)

56 (57)

0.14

Diabetes mellitus, n (%)

44 (31)

29 (29)

0.71

CKD, n (%)

62 (49)

68 (72)

0.001

 I

3 (2)

1 (1)

0.01

 II

57 (40)

22 (21)

 III

52 (37)

62 (61)

 IV ambulatory

7 (5)

7 (7)

 IV in hospital

22 (16)

10 (10)

Rescue CRT, n (%)

14 (10)

8 (8)

0.58

Beta blocker, n (%)

119 (85)

78 (79)

0.21

ACEI or ARB, n (%)

112 (80)

71 (72)

0.14

Aldosterone antagonist, n (%)

71 (51)

36 (36)

0.03

Loop diuretic, n (%)

105 (75)

85 (86)

0.04

Ivabradine, n (%)

21 (15)

11 (11)

0.38

Anticoagulation therapy, n (%)

73 (52)

59 (58)

0.33

Anti-platelet agent, n (%)

73 (52)

55 (54)

0.60

 LBBB

110 (78)

82 (80)

0.50

 RBBB

10 (7)

6 (6)

 NIVCD

3 (2)

0

 Paced QRS

18 (13)

14 (14)

LVEF (%)

28 (6)

28 (7)

0.47

CRT-D, n (%)

122 (87)

53 (52)

< 0,001

Upgrade, n (%)

41 (29)

25 (25)

0.43

Effectiveness, n (%)

70 (50)

48 (47)

0.69

One-year survival

124 (88)

85 (83)

0.31

NYHA improvement

86 (61)

67 (66)

0.72

No admission for HF

107 (76)

71 (70)

0.33

Complications, n in n patients (%)

55 in 30 (21)

27 in 15 (15)

0.19

Reintervention, n (% of complications)

24 (44)

9 (33)

0.07

Lead displacement, n (% of complications)

19 (34)

7 (26)

0.10

Implantation failure, n (% of complications)

3 (5)

5 (19)

0.23

Infection, n (% of complications)

6 (11)

3 (11)

0.59

Pneumothorax, n (% of complications)

2 (4)

2 (7)

0.74

Perforating lead, n (% of complications)

0

1 (4)

0.24

Pericardial effusion, n (% of complications)

1 (2)

0

0.39

Hematoma, n (% of complications)

0

0

NA